Skip to main content
PFE logo

PFE · Pfizer Inc

Track PFE — free
$27.50 -0.56 (-2.00%)
Market Cap
$156.97B
Shares
5.70B
Volume · Nov 19 34.97M Avg daily vol (3M) 33.42M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$27.54 Open$27.92 Day$27.44–27.99 52W close$23.67–30.79 Avg vol 30d34.1M Short int134.4M · 2.4% of shares · 4.6d Short vol28% Last earningsNov 3, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Feb 2, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Nov 17
Investor event
Pfizer Launch Products Growing 32%, Annualized Revenue Near $15-16 Billion

Pfizer CEO Albert Bourla said launch products are growing 32% this quarter and already amount to roughly $15-16 billion annualized revenue. He also said Pfizer beat analyst EPS expectations 11 times out of 11 over the last 11 quarters, and that the company expects high single-digit growth over the next five years.

4 source passages
Our launch products, they are growing at 32% this quarter, and it's accelerating, actually, the growth rather than decelerating. They are already amounting to a rounding of $15-16 billion annualized revenues and going. And we, in the last 11 quarters, we were able to beat analyst expectations 11 times out of 11 in EPS and 10 times out of 11 in revenue. As we said, with a high single-digit growth in the next five years. Open the document at this passage
Nov 3
Current report 8-K Events of Oct 30
Cecile Guegan appointed Chief Financial Officer effective November 1, 2026

Pfizer named Cecile Guegan Chief Financial Officer effective November 1, 2026, following her interim role since August 16, 2026, with a $1,300,000 base salary and $1,300,000 annual target cash incentive.

Director or officer change, or executive pay
3 source passages
On November 3, 2026, Pfizer Inc. (the “Company”) announced that the Board of Directors of the Company unanimously elected Cecile Guegan to serve as Chief Financial Officer, Executive Vice President of the Company, effective November 1, 2026 (the “Effective Date”). As reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2026, Ms. Guegan, 55, was previously appointed as the Company’s Interim Chief Financial Officer, effective August 16, 2026. (1) an annual base salary of $1,300,000; and (2) an annual target cash incentive opportunity of $1,300,000, which represents 100% of her annual base salary, which will be determined based on the salary paid during the year. Open the document at this passage
Nov 3
Earnings call
Guidance raised as non-COVID products grow

Pfizer reported third-quarter 2026 revenue of $16.6 billion, non-COVID operational growth of 7%, and raised full-year 2026 revenue guidance by $1.5 billion at the midpoint and adjusted diluted EPS guidance to $2.95-$3.05.

Read from the first part of this long document
4 source passages
Good morning, and welcome to Pfizer's earnings call. Start quarter 2026 revenue of $16.6 billion came in ahead of our expectation, with strong 7% operational revenue growth of our non-COVID products we are raising our full year 2026 revenue guidance by $1.5 billion at the midpoint We are raising and narrowing our full year 2026 adjusted diluted EPS guidance to a range of $2.95 to $3.05. Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 27
Nine-month revenue rose 2% as pretax income fell $3.3 billion

Pfizer Inc reported revenue of $46.1 billion, up 2%, while pretax income from continuing operations fell $3.3 billion to $5.9 billion. Expected cost realignment and manufacturing optimization savings rose to $6.7 billion and $3.0 billion through 2029.

Revenue $16.58B ▼ 0.4% Net income $3.24B ▼ 8.4% Diluted EPS $0.56 ▼ 9.7%
Read from the MD&A section
5 source passages
Pfizer Inc. is a research-based, global biopharmaceutical company. Total revenues increased $1.0 billion, or 2%, in the first nine months of 2026 to $46.1 billion from $45.0 billion in the first nine months of 2025, reflecting an operational increase of $412 million, or 1%, as well as a favorable impact of foreign exchange of $634 million, or 1%. The decrease in Income from continuing operations before provision/(benefit) for taxes on income of $3.3 billion, to $5.9 billion in the first nine months of 2026 from $9.2 billion in the first nine months of 2025, was primarily due to (i) charges for intangible asset impairments and certain legal matters, and increases in the fair value of our contingent consideration liabilities (all recorded in Other (income)/deductions––net), and (ii) increases in Research and development expenses, Cost of sales and Restructuring charges and certain acquisition-related costs, partially offset by (iii) a net gain in 2026 from the sale of our previous investment in ViiV (recorded in Other (income)/deductions––net), (iv) higher revenues, and (v) a decrease in Acquired in-process research and development expenses. With the additional anticipated savings, we now expect total net cost savings of approximately $6.7 billion from the program through 2029. With the additional anticipated savings, we now expect total net cost savings of approximately $3.0 billion from the program through 2029. Open the document at this passage
Nov 3
Current report 8-K
Revenue and adjusted EPS guidance raised

Pfizer Inc. reported third-quarter 2026 revenues of $16.6 billion, flat operationally year over year, and raised full-year 2026 revenue guidance to $62.0 to $64.0 billion and Adjusted diluted EPS guidance to $2.95 to $3.05.

Financial results Read from the first part of this long document
4 source passages
Third-Quarter 2026 Revenues of $16.6 Billion, Relatively Flat Year-over-Year Operationally Raises Full-Year 2026 Revenue Guidance(2) by $1.5 billion at the Midpoint to a Range of $62.0 to $64.0 billion Raises and Narrows Full-Year 2026 Adjusted(3) Diluted EPS Guidance to a Range of $2.95 to $3.05 Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2026 and raised its full-year 2026 guidance(2) for both Revenues and Adjusted(3) diluted EPS. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$63.62B
Trailing 12 months
Net income (TTM)
$4.03B
Trailing 12 months
Revenue growth YoY
-0.4%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
40.1
Trailing earnings · reciprocal yield 2.5%
FCF yield
7.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$60.85B
Latest balance sheet
Dividend yield
6.1%
Trailing 12 months
Shares change YoY
+0.6%
Year over year · more shares
Price change (1Y)
+10.3%
Trailing year
Short interest
2.4%
Latest settlement · 4.6 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 3, 2026
Q3 FY26

TL;DR. Pfizer raised 2026 revenue and adjusted diluted EPS guidance as launched and acquired products grew 32% operationally, non-COVID revenue grew 7%, cost savings supported margins, and Elrexfio and Tilrekimig advanced positive late-stage programs. Total revenue was relatively flat, reported earnings declined, COVID-19 and Prevnar revenues fell, R&D spending increased, and generic, biosimilar and loss-of-exclusivity competition remained a headwind.

Bullish
  • + Pfizer raised full-year 2026 revenue guidance by $1.5 billion at the midpoint and raised and narrowed adjusted diluted EPS guidance.
  • + Launched and acquired products grew 32% operationally in the third quarter. new
  • + Non-COVID product revenue grew 7% operationally in the third quarter. new
  • + Elrexfio met the primary endpoint of a Phase 3 multiple myeloma study and reduced the risk of disease progression or death. new
  • + Tilrekimig met its primary Phase 2 endpoint in atopic dermatitis and entered a pivotal Phase 3 program. new
Bearish
  • − A one-time $650 million Innovent-related acquired IPR&D charge reduced adjusted diluted EPS by approximately $0.10. new
  • − Full-year guidance anticipates a $1.1 billion revenue headwind from generic and biosimilar competition, while the 2027 outlook includes loss-of-exclusivity pressure. new
  • − COVID-19 product and Prevnar family revenues declined operationally in the third quarter. new
  • − Pfizer completed no share repurchases in 2026 through November 3 and did not anticipate any in its current 2026 guidance. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Mentioned in fund letters

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Low
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +2%
above
Price vs 50-day avg −4%
below
RSI (14) 33
neutral
MACD trend Negative
52-week position 54%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −9%
trailing
6-month return +7%
trailing
YTD return +11%
this year
Relative strength +13%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $29 › 200d $27 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +230 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.36% of shares out · ▼ -2.5% MoM · 4.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
2,934 holders — mid 3-yr range
Squeeze score 51
elevated · 0–100
Fundamentals
Fair
Revenue growth −2%
Y/Y
EPS growth −4%
Y/Y
Free cash flow $9.1B
Valuation P/E 39.3
below peers
Buyback $3.3B
remaining
Balance sheet $63.7B
net debt
Quant / Vol
risk profile
Low
Volatility 22%
annualized · 1-yr
Max drawdown −17%
past year
ATR 2.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 4
Latest guidance · from the 8-K filed Nov 3, 2026
Adjusted SI&A Expenses · full-year 2026 Non-GAAP Maintained $12.5B – $13.5B
May 5, 2026 $12.5B – $13.5B changed to Nov 3, 2026 $12.5B – $13.5B
Adjusted R&D Expenses · full-year 2026 Non-GAAP Raised $10.8B – $11.8B
May 5, 2026 $10.5B – $11.5B changed to Nov 3, 2026 $10.8B – $11.8B
Effective Tax Rate on Adjusted Income · full-year 2026 Non-GAAP Maintained 15%
Aug 4, 2026 15% changed to Nov 3, 2026 15%
Adjusted Diluted EPS · full-year 2026 Non-GAAP Raised $2.95 – $3.05
Aug 4, 2026 $2.80 – $3.00 changed to Nov 3, 2026 $2.95 – $3.05
Previous outlook earlier release · from the Earnings Call filed Aug 4, 2026

Still-open targets the latest release did not restate under the same label.

COVID-19 revenues · full year 2026 $4B
Total net cost savings from productivity enhancement initiative · through 2029 $9.7B
Total net savings from this program · through 2029 $9.7B
Total net cost savings from this program · through 2029 $3B
Total net cost savings · by the end of 2026 $7.2B
Net cost savings from a productivity enhancement from technology · from 2027 through 2029 $1B
Additional net cost savings · from 2027 through 2029 $2.5B
Total net savings · through 2029 $9.7B
Prior guidance period ended · from the Earnings Call filed Aug 4, 2026
Incremental $1.5 billion above the original guidance · this year $1.5B
Initial fund payment to be recorded as acquired in-process R&D e · third quarter $650M
Guided vs delivered · last 4 settled
Revenues Full-Year 2024
guided $58.5B – $61.5B
$63.63B Beat +6.0%
Revenues Full-Year 2023
guided $58B – $61B
$59.55B In line
Revenues Full-Year 2022
guided $99.5B – $102B
$101.18B In line
Total company revenue 2021
guided $81B – $82B
$81.29B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+2% Bullish
Price vs 50-day avg
−4% Neutral
RSI (14)
33 Neutral
MACD trend
Negative Bearish
52-week position
54% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $29 › 200d $27 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +230 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.36% of shares out · ▼ -2.5% MoM · 4.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
2,934 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $24 Now $28 · 54% Range high $31
vs 200-day avg +2% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Abrysvo Global Revenues $208M the three months ended June 28, 2026 filing —
Adjusted diluted EPS non-GAAP $1.52 Six Months Ended June 28, 2026 —
Adjusted R&D Expenses non-GAAP $2.73B Second-Quarter 2026 —
Comirnaty Global Revenues $261M the three months ended June 28, 2026 filing —
Effective tax rate for non-GAAP Adjusted income non-GAAP 15.5% six months ended June 28, 2026 —
Eliquis Global Revenues $2.43B the three months ended June 28, 2026 filing —
Eliquis revenue growth (operational, global) 19% Second-Quarter 2026 —
Ibrance Global Revenues $1.06B the three months ended June 28, 2026 filing —
Lorbrena Global Revenues $354M the three months ended June 28, 2026 filing —
Lorbrena revenue growth (operational, global) 37% Second-Quarter 2026 —
Non-GAAP Adjusted cost of sales non-GAAP $7.06B Six Months Ended June 28, 2026 —
Non-GAAP Adjusted income non-GAAP $8.73B Six Months Ended June 28, 2026 —
Non-GAAP Adjusted net income attributable to Pfizer Inc. common shareholders non-GAAP $4.44B the three months ended June 28, 2026 filing —
Non-GAAP Adjusted other (income)/deductions—net non-GAAP $496M Six Months Ended June 28, 2026 —
Non-GAAP Adjusted selling, informational and administrative expenses non-GAAP $6.26B Six Months Ended June 28, 2026 —
Nurtec ODT/Vydura Global Revenues $421M the three months ended June 28, 2026 filing —
Padcev Global Revenues $667M the three months ended June 28, 2026 filing —
Padcev revenue growth (operational, global) 23% Second-Quarter 2026 —
Paxlovid Global Revenues $21M the three months ended June 28, 2026 filing —
Prevnar family Global Revenues $1.34B the three months ended June 28, 2026 filing —
Revenues of Launched and Acquired Products growth (operational) 18% Second-Quarter 2026 —
Total revenues excluding contributions from Comirnaty and Paxlovid (operational growth) 5% the second quarter of 2026 filing —
Total revenues operational increase (growth excluding foreign exchange) 1% the second quarter of 2026 filing —
Vyndaqel family Global Revenues $1.76B the three months ended June 28, 2026 filing —
Vyndaqel family revenue growth (operational, global) 8% Second-Quarter 2026 —
Xtandi Global Revenues $534M the three months ended June 28, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PFE
Pfizer Inc
this stock
$156.97B +10.6% -1.6% 39.3 2.4%
LLY
ELI LILLY & Co
$1.27T +25.7% +44.7% 43.9 0.8%
JNJ
Johnson & Johnson
$643.09B +29.1% +6.0% 40.6 0.7%
ABBV
AbbVie Inc.
$501.19B +24.1% +8.6% 48.8 0.9%
MRK
Merck & Co., Inc.
$327.41B +26.2% +1.3% 136.9 1.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
2,934
% held
66.1%
Net QoQ
-46.5M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
1,077
View
Short & Settlement
Short Interest Falling
Shares short
134.4M
Days to cover
4.6d
Change
-3.4M sh
View
Short Volume
Short vol %
28%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
79.0K
Value
$2.4M
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
47.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Thomas H Tuberville
Amount
$15.0K–$50.0K
Traded
Jun 8, 2026
View
Financials
Financials
Revenue (FY)
$62.6B
Net income (FY)
$7.8B
EPS diluted
$1.36
View
Buybacks
Authorized
$6.8B
Remaining
$3.3B
Spent Remaining
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
21

Pfizer CEO Albert Bourla said launch products are growing 32% this quarter and already amount to roughly $15-16 billion annualized revenue. He also said Pfizer beat analyst EPS expectations 11 times out of 11 over the last 11 quarters, and that the company expects high single-digit growth over the next five years.

View
Proposed Sales
Value
$1.4M
Shares
59.8K
Filed
May 23, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Pfizer Enters into Exclusive Lice…
Published
Nov 18, 2026
View

Performance

5D 20D 120D MTD YTD
PFE -4.5% -9.5% +7.5% -9.8% +10.6%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +1.0% -3.2% +13.1% -4.5% +5.6%

Capital returns

Latest dividend
$0.43 / share · ex Nov 6, 2026
Raised 2.4%
Paid (TTM)
$1.72 / share · 4 payouts
Dividend yield (TTM, derived)
6.25%
Full dividend history
Buyback program · as of Sep 27, 2026
Authorized
$6.80B
Spent (derived)
$3.50B
Remaining
$3.30B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 78003 CUSIP 717081103 13F (30d) 2589 filings 2394 filers Visit website Investor relations